Modified RSV F proteins and methods of their use
AssigneeNovavax, Inc.
InventorsPeter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Life of this patent
Estimating the term…
Abstract
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Claims16
An immunogenic composition comprising a trimeric RSV F protein and a pharmaceutically acceptable carrier, wherein the RSV F protein comprises a deletion of up to 10 amino acids corresponding to the fusion domain of residues 137-146 of SEQ ID NO:
- 2, wherein the RSV F protein induces the production of neutralizing antibodies, wherein the RSV F protein is produced in a Spodoptera frugiperda Sf9 cell.
A method of eliciting an immune response in a host, said method comprising administering a trimeric RSV F protein comprising a deletion of up to 10 amino acids corresponding to the fusion domain of residues 137-146 of SEQ ID NO:2, wherein the RSV F protein induces the production of neutralizing antibodies, wherein the RSV F protein is produced in a Spodoptera frugiperda Sf9 cell.
A method of producing a trimeric RSV F protein, the method comprising:
- (a) transforming a Spodoptera frugiperda 519 host cell to express a nucleic acid encoding an RSV F protein comprising a deletion of up to 10 amino acids corresponding to the fusion domain of residues 137-146 of SEQ ID NO:2,
- (b) culturing said host cell under conditions conducive to the production of said RSV F protein.
Dependencies are inferred from the claim text.